"Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review" [Cancer Treatment Reviews 32(5) (2006) 333-347] (DOI:10.1016/j.ctrv.2006.03.003);Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review

Cancer Treatment Reviews

Volumn 32, Issue 5, 2006, Pages 333-347

  Rossana, Berardi ^a   Mario, Scartozzi ^a   Federica, Freddari ^a   Michela, Squadroni ^a   Alfredo, Santinelli ^a   Italo, Bearzi ^a   Guidalberto, Fabris ^a   Stefano, Cascinu ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Biliary tract cancer; Chemotherapy; Genetics; Molecular biology; Target therapies

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CAPECITABINE; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; EXATECAN; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MITOMYCIN C; OXALIPLATIN; PROTEIN BCL 2; PROTEIN P53; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ACUTE TOXICITY; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; LIVER DYSFUNCTION; MEDICAL LITERATURE; NEUROTOXICITY; NEUTROPENIA; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

EID: 33746197936     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.03.007     Document Type: Erratum

References (95)

1. Carriaga M.T., and Henson D.E. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 75 Suppl. 1 (1995) S171-S190
2. Fong Y., Kemeny N., and Lawrence T.S. Cancer of the liver and biliary tree. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (2001), Lippincott-Raven, Philadelphia (PA) 1162-1203
3. Fong Y., Blumgart L.H., Lin E., Fortner J.G., and Brennan M.F. Outcome of treatment for distal bile duct cancer. Br J Surg 83 12 (1996) 1712-1715
4. Yeo C.J., Cameron J.L., Sohn T.A., Lillemoe K.D., Pitt H.A., Talamini M.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes. Ann Surg 226 (1997) 248-257
5. Wade T.P., Prasad C.N., Virgo K.S., and Johnson F.E. Experience with distal bile duct cancers in US Veterans Affairs hospitals. J Surg Oncol 64 (1997) 242-245
6. Lazcano-Ponce E.C., Miquel J.F., Munoz N., Herrero R., Ferrecio C., Wistuba I.I., et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51 (2001) 349-364
7. Jones Jr. D.V., Lozano R., Hoque A., Markowitz A., and Patt Y.Z. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14 8 (1996) 2306-2310
8. Sanz-Altamira P.M., O'Reilly E., Stuart K.E., Raeburn L., Steger C., Kemeny N.E., et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 12 4 (2001) 501-504
9. Sanz-Altamira P.M., Ferrante K., Jenkins R.L., Lewis W.D., Huberman M.S., and Stuart K.E. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82 12 (1998) 2321-2325
10. Hejna M., Pruckmayer M., and Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34 (1998) 977-986
11. Glimelius B., Hoffman K., Sjoden P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 (1996) 593-600
12. Choi C.W., Choi I.K., Seo J.H., Kim B.S., Kim J.S., Kim C.D., et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 23 4 (2000) 425-428
13. Raderer M., Hejna M.H., Valencak J.B., Kornek G.V., Weinlander G.S., Bareck E., et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56 3 (1999) 177-180
14. Chen J.S., Lin Y.C., Jan Y.Y., and Liau C.T. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs 12 4 (2001) 339-343
15. Patt Y.Z., Jones Jr. D.V., Hoque A., et al. Phase II trial of intravenous fluorouracil and subcunaneous interferon alpha-2b for biliary tract cancer. J Clin Oncol 14 (1996) 2311-2315
16. Patt Y.Z., Hassan M.M., Lozano R.D., Waugh K.A., Hoque A.M., Frome A.I., et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7 11 (2001) 3375-3380
17. Habara K., Ajiki T., Kamigaki T., Nakamura T., and Kuroda Y. High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. Jpn J Cancer Res 92 (2001) 1127-1132
18. Etienne M., Cheradame S., Fischel J.L., Formento P., Dassonville O., Renee N., et al. Response to fluouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13 (1995) 1663-1670
19. Okada S., Ishii H., Nose H., Yoshimori M., Okusaka T., Aoki K., et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51 6 (1994) 515-517
20. Ducreux M., Rougier P., Fandi A., Clavero-Fabri M.C., Villing A.L., Fassone F., et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9 6 (1998) 653-656
21. Ducreux M., Van Cutsem E., Van Laethem J.L., Gress T.M., Jeziorski K., Rougier P., et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 41 3 (2005) 398-403
22. Taieb J., Mitry E., Boige V., Artru P., Ezenfis J., Lecomte T., et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 13 8 (2002) 1192-1196
23. Rao S., Cunningham D., Hawkins R.E., Hill M.E., Smith D., Daniel F., et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92 9 (2005) 1650-1654
24. Malik I.A., Aziz Z., Zaidi S.H., and Sethuraman G. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 26 2 (2003) 174-177
25. Nehls O., Klump B., Arkenau H.T., Hass H.G., Greschniok A., Gregor M., et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 87 7 (2002) 702-704
26. Fink D., Aebi S., and Howell S.B. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4 1 (1998) 1-6
27. Hanford M.G., Rushton B.C., Gowen L.C., and Farber R.A. Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair. Oncogene 16 (1998) 2389-2393
28. Konya N., Kitajima Y., and Miyazaki K. Mutation analysis of K-ras and beta-cathenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. Int J Mol Med 11 1 (2003) 65-69
29. Rashid A., Ueki T., Gao Y.T., Houlihan P.S., Wallace C., Wang B.S., et al. K-ras mutation, p53 overexpression and microsatellite instability in biliary tract cancer: a population based study in China. Clin Cancer Res 8 10 (2002) 3156-3163
30. Adlard J.W., Richman S.D., Seymour M.T., and Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3 27 (2002) 75-82
31. Xinjian L., Krishnan R., Misako M., Akira K., Randolf D.C., and Stephen B. Howell p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61 (2001) 1508-1516
32. Gourdier I., Del Rio M., Crabbe L., Candeil L., Copois V., Ychou M., et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529 2-3 (2002) 232-236
33. Ellis P.A., Norman A., Hill A., O'Brien M.E., Nicolson M., Hickish T., et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31A 10 (1995) 1594-1598
34. Maitra R., Halpin P.A., Karlson K.H., Page R.L., Paik D.Y., Leavitt M.O., et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J 355 Pt 3 (2001) 617-624
35. Leontieva O.V., Preobrazhenskaya M.N., and Bernacki R.J. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Invest New Drugs 20 1 (2002) 35-48
36. Gustafson D.L., and Long M.E. Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: implications for pharmacokinetics in multiple dosing regimens. Chem Biol Interact 138 1 (2001) 43-57
37. Cao L., Duchrow M., Windhovel U., Kujath P., Bruch H.P., and Broll R. Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gallbladder cancer tissues. Eur J Cancer 34 10 (1998) 1612-1617
38. Alberts S.R., Fishkin P.A., Burgart L.J., Cera P.J., Mahoney M.R., Morton R.F., et al., North Central Cancer Treatment Group. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 32 2-3 (2002) 107-114
39. Saleem A., Edwards T.K., Rasheed Z., and Rubin E.H. Mechanisms of resistance to camptothecins. Ann NY Acad Sci 922 (2000) 46-55
40. Rubin E.H., Li T.K., Duann P., and Liu L.F. Cellular resistance to topoisomerase poisons. Cancer Treat Res 87 (1996) 243-260
41. Li X.G., Haluska Jr. P., Hsiang Y.H., Bharti A., Kufe D.W., and Rubin E.H. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann NY Acad Sci 803 (1996) 111-127
42. Xu Y., and Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13 (2002) 1841-1851
43. Fujimori A., Harker W.G., Kohlhagen G., Hoki Y., and Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55 (1995) 1339-1346
44. Chu X.Y., Suzuki H., Ueda K., Kato Y., Akiyama S., and Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 288 (1999) 735-741
45. Pazdur R., Royce M.E., Rodriguez G.I., Rinaldi D.A., Patt Y.Z., Hoff P.M., et al. Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22 1 (1999) 78-81
46. Papakostas P., Kouroussis C., Androulakis N., Samelis G., Aravantinos G., Kalbakis K., et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 37 15 (2001) 1833-1838
47. Kuhn R., Hribaschek A., Eichelmann K., Rudolph S., Fahlke J., and Ridwelski K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 20 3 (2002) 351-356
48. Hasegawa S., Miyoshi Y., Egawa C., Ishitobi M., Taguchi T., Tamaki Y., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9 8 (2003) 2992-2997
49. Liu B., Staren E., Iwamura T., Appert H., and Howard J. Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines. World J Gastroenterol 7 5 (2001) 855-859
50. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272 (1997) 17118-17125
51. Ranganathan S., Benetatos C.A., Colarusso P.J., Dexter D.W., and Hudes G.R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77 (1998) 562-566
52. Carles G., Braguer D., Dumontet C., Bourgarel V., Goncalves A., Sarrazin M., et al. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 80 (1999) 1162-1168
53. Burkhart C.A., Kavallaris M., and Band H. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471 (2001) 01-09
54. Blade K., Menick D.R., and Cabral F. Overexpression of class I, II or IVb bet a-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 112 (1999) 2213-2220
55. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L., et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88 12 (2003) 1963-1970
56. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29 6 Suppl. 20 (2002) S40-S45
57. Mezger J., Sauerbruch T., Ko Y., Wolter H., Funk C., and Glasmacher A. Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 21 (1998) 232-234
58. Penz M., Kornek G.V., Raderer M., Ulrich-Pur H., Fiebiger W., Lenauer A., et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12 2 (2001) 183-186
59. Lin M.H., Chen J.S., Chen H.H., and Su W.C. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49 3 (2003) 154-158
60. Valencak J., Kornek G.V., Raderer M., Ulrich-Pur H., Krauss G., Greul R., et al. Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie 22 (1999) 498-501
61. Gebbia V., Giuliani F., Maiello E., Colucci G., Verderame F., Borsellino N., et al. Treatment of inperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluoruracil: results of a multicenter phase II study. J Clin Oncol 19 (2001) 4089-4091
62. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54 15 (1994) 4138-4143
63. Obata T., Endo Y., Tanaka M., Uchida H., Matsuda A., and Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res 92 (2001) 793-798
64. Yih-Gang G., Bingsen Z., Edward H., Shu M., and Yun Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59 (1999) 4204-4207
65. Patt Y.Z., Hassan M.M., Aguayo A., Nooka A.K., Lozano R.D., Curley S.A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 3 (2004) 578-586
66. Knox J.J., Hedley D., Oza A., Feld R., Siu L.L., Chen E., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 10 (2005) 2332-2338
67. Philip P.A., Mahoney M.R., Thomas J.P., Pitot H.C., Donehower R., Kim G.P., et al. Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer. J Clin Oncol 22 14S (2004) 4025
68. Milella M., Gelibter A., Di Cosimo S., Bria E., Ruggeri E.M., Carlini P., et al. Exploratory phase II study of celecoxib and infusional fluorouracil as second-line treatment for advanced pancreatic (PDAC) and biliary tree cancer (BTC). J Clin Oncol 22 14S (2004) 4183
69. Abou-Alfa G.K., O'Reilly E.M., Rowinsky E., Patt Y.Z., Schwartz G.K., Kelsen D.P., et al. A phase II study of intravenous DX-8951f administered daily for five days, every three weeks to patients with biliary tree cancer (cholangiocarcinoma and gallbladder cancer). J Clin Oncol (2004) abstr. 94
70. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319 (1986) 230-234
71. Gusterson B.A., Gelber R.D., Goldhirsch A., Price K.N., Save-Soderborgh J., Anbazhagan R., et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10 (1992) 1049-1056
72. Kern J.A., Slebos R.J., Top B., Rodenhuis S., Lager D., Robinson R.A., et al. C-erbB2 expression and codon 12 k-ras both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93 (1994) 516-520
73. Chow N.H., Huang S.M., Chan S.H., Mo L.R., Hwang M.H., and Su W.C. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 15 3 (1995) 1055-1059
74. Collier J.D., Guo K., Mathew J., May F.E., Bennett M.K., Corbett I.P., et al. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol 14 (1992) 377-380
75. Voravud N., Foster C.S., Gilbertson J.A., Sikora K., and Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 20 12 (1989) 1163-1168
76. Kim Y.W., Huh S.H., Park Y.K., Yoon T.Y., Lee S.M., and Hong S.H. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep 8 5 (2001) 1127-1132
77. Terada T., Ashida K., Endo K., Horie S., Maeta H., Matsunaga Y., et al. C-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 33 (1998) 325-331
78. Mikami T., Yanagisawa N., Baba H., Koike M., and Okayasu I. Association of bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer 85 2 (1999) 318-325
79. Ito Y., Takeda T., Sasaki Y., Sakon M., Monden M., Yamada T., et al. Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncology 59 1 (2000) 63-67
80. Nonomura A., Ohta G., Nakanuma Y., Izumi R., Mizukami Y., Matsubara F., et al. Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF), and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 8 3 (1988) 157-166
81. Ito Y., Takeda T., Sasaki Y., Sakon M., Yamada T., Ishiguro S., et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197 2 (2001) 95-100
82. Folkman J. Tumor angiogenesis and tissue factors. Nat Med 2 (1996) 167-168
83. Nakashima T., Kondoh S., Kitoh H., Ozawa H., Okita S., Harada T., et al. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int J Mol Med 11 1 (2003) 33-39
84. Hida Y., Morita T., Fujita M., Miyasaka Y., Horita S., Fujioka Y., et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 19 3B (1999) 2257-2260
85. Furubo S., Harada K., Shimonishi T., Katayanagi K., Tsui W., and Nakanuma Y. Protein expression and genetic alterations of p5v3 and ras in intrahepatic cholangiocarcinoma. Histopathology 35 3 (1999) 230-240
86. Batheja N., Suriawinata A., Saxena R., Ionescu G., Schwartz M., and Thung S.N. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol 13 12 (2000) 1265-1268
87. Arora D.S., Ramsdale J., Lodge J.P., and Wyatt J.I. P53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology 34 6 (1999) 497-501
88. Matsubara T., Funabiki T., Jinno O., Sakurai Y., Hasegawa S., Imazu H., et al. P53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 6 3 (1999) 286-293
89. Boberg K.M., Schrumpf E., Bergquist A., Broome U., Pares A., Remotti H., et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 32 3 (2000) 374-380
90. Wistuba I.I., and Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 6 (1999) 237-244
91. Itoi T., Takei K., Shinohara Y., Takeda K., Nakamura K., Horibe T., et al. K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 49 1 (1999) 30-37
92. Ohashi K., Tstsumi M., Nakajima Y., Nakano H., and Konishi Y. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer 74 6 (1996) 930-935
93. Isa T., Tomita S., Nakachi A., Miyazato H., Shimoji H., Kusano T., et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49 45 (2002) 604-608
94. Watanabe H., Ha A., Hu Y.X., Ohtsubo K., Yamaguchi Y., Motoo Y., et al. K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer 86 8 (1999) 1441-1448
95. Yip-Schneider M.T., Sweeney C.J., Jung S.H., Crowell P.L., and Marshall M.S. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 298 3 (2001) 976-985